Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol for slowing progression of cerebral white matter hyperintensities
ChiCTR-TRC-14005054Phase 4Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of cilostazol in Cerebral Small Vessel Disease (CSVD) and white matter hyperintensities (WMH) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoints: Change in white matter hyperintensity volume on MRI and Change in other MRI brain measures and clinical measures. Started Sep 2014; status: recruiting.
02
Drugs
cilostazol
03
Conditions
Cerebral Small Vessel Disease (CSVD)white matter hyperintensities (WMH)
Beyond the preview
Go deeper on ChiCTR-TRC-14005054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14005054.